US Lawmakers Call for Sanctions Against China's WuXi Biotech
Originally Published 1 year ago — by Endpoints News
Lawmakers' explosive charges have put a global spotlight on China's WuXi, a major player in the biopharma industry, which is now facing increased scrutiny. The relationship between biopharma companies and global CRO/CDMOs can be disrupted by various issues such as regulatory issues, production snags, and questions about team leadership, impacting long-term projects with substantial stakes.